Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 21
- Registration Number
- NCT06969612
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
- Conditions
- Esophageal Cancer Stage III
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06965829
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 31
- Registration Number
- NCT06951841
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- Drug: Total neoadjuvant therapy (TNT)
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- brenner baruch
- Target Recruit Count
- 134
- Registration Number
- NCT06940388
- Locations
- 🇩🇪
Johannes Gutenberg-University Clinic, Mainz, Germany 1.Dept. Medicine, Prof. Peter R. Galle, Mainz, Germany
🇮🇱Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Interventions
- Drug: Neoadjuvant Cryoablation Combined with Tislelizumab and ChemotherapyProcedure: Surgery
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 38
- Registration Number
- NCT06939127
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Testing Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy
- Conditions
- Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 76
- Registration Number
- NCT06919705
- Locations
- 🇨🇦
610 University Health Network, Toronto, Ontario, Canada
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT06916494
- Locations
- 🇨🇳
First Affiliated Hospital of Chongqing Medical University, ChongQing, Chongqing, China
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric AdenocarcinomaGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaPeritoneal Metastasis
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06914687
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 172
- Registration Number
- NCT06914011
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
- Conditions
- CholangiocarcinomaBiliary Tract Cancer (BTC)
- Interventions
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06903273
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.